Komori
Intramart (3850) · FactReframed

First-quarter R&D activity expenses: ¥25,640 thousand

First written in FY2018-Q1. 26 of 27 entries say "Reframed", first in FY2018-Q2. Latest entry: FY2026.

27entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseReframedFY2018-Q2 – FY20262017: 220172018: 420182019: 420192020: 420202021: 220212022: 320222023: 320232024: 320242025: 120252026: 12026
Same theme, other companies
Recognition and Disclosure of R&D ExpensesA theme 73 companies write about · 0 as a headwind · 21 as a tailwind

Intramart moved to the "Worse" side of this theme in 2018.

0 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 73 companies compared. The sentences above are computed from all 73.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「During the consolidated fiscal year, the company focused on development methods based on AI and the implementation of AI applications in the enterprise sector, and pursued research and development mainly in the following technology fields. Total research and development expenses for the consolidated fiscal year were ¥217.802 million.」

    The reporting period for research and development expenses changed from the interim period to the full fiscal year, and the company disclosed full-year total expenses of ¥217.802 million. It also stated that it had focused its research and development on AI-based initiatives.
  2. FY2026-H1ReframedAnnual report

    「The amount spent on research and development activities during the interim consolidated period was ¥50.454 million.」

    The reporting period for research and development expenses changed from the previous fiscal year's full-year period to the current interim consolidated period, and the company disclosed ¥50.454 million.
  3. FY2025-H1ReframedAnnual report

    「The amount spent on research and development activities during the interim consolidated period was ¥38.083 million.」

    The reporting period for research and development expenses changed from the previous fiscal year's full-year period to the current interim consolidated period, and the company disclosed ¥38.083 million.
  4. FY2024ReframedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥93.281 million.」

    The reporting period for research and development expenses changed from the quarterly cumulative period to the full fiscal year, and the company disclosed annual total expenses of ¥93.281 million for the fiscal year ending March 2024.
  5. FY2024-Q3ReframedAnnual report

    「The amount spent on research and development activities during the third-quarter cumulative consolidated period was ¥69.634 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥69.634 million.
  6. FY2024-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥42.758 million.」

    The reporting period for research and development expenses changed from the cumulative first quarter of the fiscal year ending March 2024 to the cumulative second quarter, and the company disclosed ¥42.758 million.
  7. FY2024-Q1ReframedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥23.214 million.」

    The reporting period for research and development expenses changed from the full fiscal year ending March 2023 to the cumulative first quarter of the fiscal year ending March 2024, and the company disclosed ¥23.214 million.
  8. FY2023-Q3ReframedAnnual report

    「The amount spent on research and development activities during the third-quarter cumulative consolidated period was ¥59.386 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥59.386 million.
  9. FY2023-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥39.743 million.」

    The reporting period for research and development expenses changed from the cumulative first quarter of the fiscal year ending March 2023 to the cumulative second quarter, and the company disclosed ¥39.743 million.
  10. FY2023-Q1ReframedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥16.948 million.」

    The reporting period for research and development expenses changed from the cumulative third quarter of the fiscal year ending March 2022 to the cumulative first quarter of the fiscal year ending March 2023, and the company disclosed ¥16.948 million.
  11. FY2022-Q3ReframedAnnual report

    「The amount spent on research and development activities during the third-quarter cumulative consolidated period was ¥57.623 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥57.623 million.
  12. FY2022-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥41.366 million.」

    The reporting period for research and development expenses changed from the first-quarter cumulative period to the second-quarter cumulative period, and the company disclosed ¥41.366 million.
  13. FY2021-Q3ReframedAnnual report

    「The amount spent on research and development activities during the third-quarter cumulative consolidated period was ¥75.583 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥75.583 million.
  14. FY2021-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥57.361 million.」

    The reporting period for research and development expenses changed from the first-quarter cumulative period to the second-quarter cumulative period, and the company disclosed ¥57.361 million.
  15. FY2021-Q1ReframedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥32.478 million.」

    For research and development expenses, the reporting period changed to the cumulative first quarter of the fiscal year ending March 2021, and the company disclosed ¥32.478 million.
  16. FY2020ReframedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥107.441 million.」

    The reporting period for research and development expenses changed from the quarterly cumulative period to the full fiscal year, and the company disclosed annual total expenses of ¥107.441 million, up from ¥95.988 million in the previous fiscal year.
  17. FY2020-Q3ReframedAnnual report

    「The amount spent on research and development activities during the third-quarter cumulative consolidated period was ¥76.412 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥76.412 million.
  18. FY2020-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥44.867 million.」

    The reporting period for research and development expenses changed from the first-quarter cumulative period to the second-quarter cumulative period, and the company disclosed ¥44.867 million.
  19. FY2020-Q1ReframedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥20.266 million.」

    The reporting period for research and development expenses changed from the full fiscal year to the cumulative first quarter of the fiscal year ending March 2020, and the company disclosed ¥20.266 million.
  20. FY2019ReframedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥95.988 million.」

    The reporting period for research and development expenses changed from the third-quarter cumulative period to the full fiscal year, and the company disclosed annual total expenses of ¥95.988 million.
  21. FY2019-Q3ReframedAnnual report

    「The amount spent on research and development activities across the group during the third-quarter cumulative consolidated period was ¥80.706 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥80.706 million.
  22. FY2019-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥53.049 million.」

    The reporting period for research and development expenses changed from the first-quarter cumulative period to the second-quarter cumulative period, and the company disclosed ¥53.049 million.
  23. FY2019-Q1ReframedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥27.106 million.」

    The reporting period for research and development expenses changed from the full fiscal year to the first-quarter cumulative period, and the company disclosed ¥27.106 million.
  24. FY2018ReframedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥94.616 million.」

    The reporting period for research and development expenses changed from the quarterly cumulative period to the full fiscal year, and the company disclosed annual total expenses of ¥94.616 million.
  25. FY2018-Q3ReframedAnnual report

    「The amount spent on research and development activities across the group during the third-quarter cumulative consolidated period was ¥99.769 million.」

    The reporting period for research and development expenses changed from the second-quarter cumulative period to the third-quarter cumulative period, and the company disclosed ¥99.769 million.
  26. FY2018-Q2ReframedAnnual report

    「The amount spent on research and development activities during the second-quarter cumulative consolidated period was ¥68.117 million.」

    The reporting period for research and development expenses changed from the first-quarter cumulative period to the second-quarter cumulative period, and the company disclosed ¥68.117 million.
  27. FY2018-Q1First statedAnnual report

    「The amount spent on research and development activities across the group during the first-quarter cumulative consolidated period was ¥25.640 million.」

    The company disclosed group-wide research and development expenses of ¥25.640 million for the first-quarter cumulative period.
Moved together

"Nine-month cumulative net sales decrease, operating profit increase, and ordinary and net income decreases" moved the same way as this thread, in the same document, in 26 of its 27 moves.

261310754★123456
  1. ★This thread
  2. 1Nine-month cumulative net sales decrease, operating profit increase, and ordinary and net income decreases26×
  3. 2Sluggish performance in the services business due to a decline in large-scale SI projects13×
  4. 3Uncertainty over the outlook for the economy and external demand against the backdrop of the UK's withdrawal from the EU and other factors10×
  5. 4Shift in sales toward higher-tier models of the core platform product7×
  6. 5Occurrence of contracts expected to incur losses5×
  7. 6Control by and Transaction Dependence on NTT DATA Group4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Intramart's next results are scheduled for 2026-10-28. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.